Fate therapeutics inc (FATE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-111,909

-98,149

-85,874

-76,047

-72,223

-66,598

-63,068

-56,970

-46,961

-42,952

-38,395

-36,448

-35,211

-33,462

-32,968

-31,117

-30,488

-29,992

-28,779

-28,496

-26,784

-25,883

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,458

2,193

1,897

1,620

1,358

1,204

1,167

1,101

1,051

971

884

858

860

881

888

857

786

687

602

530

501

496

0

0

0

Stock-based compensation

20,455

17,410

14,611

11,680

8,779

6,293

5,404

4,633

4,121

3,606

3,530

3,441

3,254

3,184

2,845

2,637

2,589

2,400

2,532

2,485

2,171

2,434

0

0

0

Amortization of debt discounts and debt issuance costs

-

115

66

70

72

76

76

76

76

81

90

104

123

139

155

167

172

176

139

97

60

24

0

0

0

Accretion and amortization of premiums and discounts on investments, net

202

478

594

426

265

335

303

223

99

25

8

-40

-115

-171

0

0

0

-

-

-

-

-

-

-

-

Amortization of collaboration contract asset

681

620

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest expense

-

-

332

347

360

373

373

368

336

321

323

346

412

492

553

606

644

651

585

479

321

167

0

0

0

Deferred rent

-

-

-

-

-

-192

-406

-608

-882

-1,085

-817

-551

-272

7

16

24

21

24

33

44

53

52

0

0

0

Deferred revenue

-6,909

-8,526

-3,387

8,517

10,653

12,259

7,895

-2,105

-3,157

-2,105

-5,855

-4,803

-2,697

-2,401

0

0

0

-

-

-

-

-

-

-

-

Stock-based milestone charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

2,067

1,911

585

1,155

1,382

2,010

1,373

1,128

339

428

75

-285

194

381

314

784

522

107

378

127

147

146

0

0

0

Accounts payable and accrued expenses

2,219

4,277

3,102

618

2,323

4,254

5,472

4,113

1,507

2,511

1,174

1,534

2,448

1,561

1,062

789

998

477

686

1,011

389

163

0

0

0

Right-of-use assets and lease liabilities, net

2,398

774

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-92,355

-83,175

-68,660

-52,378

-43,592

-38,650

-38,351

-44,564

-41,913

-36,817

-33,647

-31,394

-30,026

-29,823

-29,242

-28,857

-19,274

-18,397

-17,581

-15,971

-23,539

-22,419

0

0

0

Investing activities
Purchases of property and equipment

6,719

7,395

5,922

5,382

3,865

2,303

1,983

1,621

1,754

1,725

968

639

434

457

595

1,217

1,224

1,498

1,591

1,123

936

882

0

0

0

Purchases of investments

-

-

-

-

-

55,660

55,660

55,660

55,660

39,971

39,971

43,480

43,480

19,675

0

0

0

-

-

-

-

-

-

-

-

Maturities of investments

113,144

98,800

81,550

58,000

56,000

57,500

54,000

54,000

41,750

31,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-142,433

-157,453

-30,554

-53,564

52,135

-463

-3,643

-3,281

-15,664

-10,196

-17,421

-30,601

-26,146

-4,114

-10,270

-11,383

-17,390

-1,498

-1,591

-1,123

-936

-882

0

0

0

Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs

2,275

2,522

2,888

3,858

3,345

2,693

1,947

920

777

205

191

109

73

186

202

399

492

420

0

0

0

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance costs from public offering of common stock

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from CIRM award

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal repayments of long–term debt

-

-

-

-

-

-

-

-

-

10,764

12,739

7,968

7,827

7,689

0

0

0

-

-

-

-

1,750

0

0

0

Net cash provided by financing activities

150,121

149,928

165,555

141,215

141,683

140,780

182,115

53,049

49,881

47,356

57,200

57,188

57,293

57,737

3,754

-5,066

33,802

35,603

46,499

56,258

18,943

18,366

0

0

0

Net change in cash, cash equivalents and restricted cash

-84,667

-90,700

66,341

35,273

150,226

101,667

140,121

5,204

-7,696

343

6,132

-4,807

1,121

23,800

-35,758

-45,306

-2,862

15,708

27,327

39,164

-5,532

-4,935

0

0

0

Supplemental disclosure of cash flow information
Interest paid

-

2,291

1,251

1,255

1,252

1,242

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment in accounts payable

-537

602

791

617

1,262

37

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of use assets obtained in exchange for lease obligations

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-